Abstract
Still no effective HIV-1 prophylactic or therapeutic vaccines are available. However, as the proportion of HIV-1-infected individuals on antiretroviral treatment is increasing, knowledge about the residual immune response is important for the possible development of an HIV-1 vaccine.
| Original language | English |
|---|---|
| Journal | Journal of Acquired Immune Deficiency Syndromes (1999) |
| Volume | 63 |
| Issue number | 4 |
| Pages (from-to) | 418-27 |
| Number of pages | 10 |
| ISSN | 1525-4135 |
| DOIs | |
| Publication status | Published - 1 Aug 2013 |
Keywords
- Antiretroviral Therapy, Highly Active
- Antiviral Agents
- CD4 Lymphocyte Count
- CD4-Positive T-Lymphocytes
- CD8-Positive T-Lymphocytes
- Cells, Cultured
- Cytokines
- Female
- HIV Core Protein p24
- HIV Infections
- HIV Integrase
- HIV-1
- HLA Antigens
- Humans
- Male
- RNA, Viral
- Viral Load
- nef Gene Products, Human Immunodeficiency Virus
Fingerprint
Dive into the research topics of 'HIV-1-infected individuals in antiretroviral therapy react specifically with polyfunctional T-cell responses to Gag p24'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS